Victrex plc with ticker (LON:VCT) now has a potential upside of 27.5% according to Barclays.
Barclays set a target price of 2,190 GBX for the company, which when compared to the Victrex plc share price of 1,588 GBX at opening today (23/12/2022) indicates a potential upside of 27.5%. Trading has ranged between 1,522 (52 week low) and 2,502 (52 week high) with an average of 159,578 shares exchanging hands daily. The market capitalisation at the time of writing is £1,399,777,224.
Victrex plc is a United Kingdom-based company, which manufactures and sells polymers worldwide. The Company develops polyetheretherketone (PEEK) and PAEK polymer solutions, and semi-finished and finished parts. The Company also offers specialist solutions for medical device manufacturers; sells thermoplastic polymer components; and engages in trading activities. The Company operates through two segments: Industrial and Medical. The Industrial segment is focused on the Company’s energy and industrial, value-added resellers (VAR), automotive, aerospace and electronics markets. The Medical segment is focused on providing specialist solutions for medical device manufacturers. The Company’s subsidiaries include Victrex Manufacturing Limited, Invibio Limited, Invibio Knees Limited, Invibio Device Component, Manufacturing Limited and Juvora Limited.
Victrex plc 27.5% potential upside indicated by Barclays
[shareaholic app="share_buttons" id_name="post_below_content"]
- Written by: Charlotte Edwards
Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
Victrex plc (LON:VCT) announces interim results for the 6 months ended 31 March 2024, highlighting revenue, profit, and growth targets. CEO Jakob Sigurdsson provides insights.
Victrex plc is a world leader in high-performance polymer solutions. In their Q1 2024 statement, they report a decline in revenue and volume but highlight progress in certain end-markets. They also discuss their financial position and cost actions. CEO Jakob Sigurdsson remains optimistic about the opportunity for progress in the future.